Creation
Draft
Initial
Detailed
Accepted
Adoption
Signpost/Archive
Idea Description
Supplementary Information
Detailed Submission Data
Innovation 'Elevator Pitch':
DLS Supported Self Management puts patients in control of their own health; connecting lifestyle goals to health benefits, sharing data with health professionals and making virtual clinics a reality. 
Overview of Innovation:
DLS Supported Self Management consists of two modules which are both available through the web, android and iOS apps.
 
The first, prescribed by health professionals or through self-referral, is a lifestyle plan, which will help patients, and their health professionals map out important lifestyle goals related to specific conditions and pathways.
 
The lifestyle plan will connect existing monitoring devices and lifestyle apps, and allow this data to be shared with care teams and health professionals, giving them the visibility to provide professional support, encouragement and advice to the patient when it is needed most.  Once set up, it will become the coach needed to help the patient stick to their plan offering reminders, encouragement, advice and feedback based on progress, as well as access to a range of prescribed self-care courses and condition focused support groups.
 
The second module will bridge the gap between the patient and clinical worlds, integrating directly into Primary care clinical systems and providing a seamless workflow. This includes:
  • visibility on each patients lifestyle plan, patient collated data and comments made by the patients care team (including non-medical data).
  • A virtual clinic with a dashboard of patients within that specific clinic (e.g) diabetes and a RAG view of the patient data within each record.
  • Easy access to communications tools such as video calls and the phone, the ability to prescribe self-care content and the facility to send, receive and record patient messages.
Both modules will sit on a platform that will provide secure identity management, deliver robust management of patient consent and through a developer platform, will allow third parties to build against the system, enable access for open and paid API’s and deliver bespoke websites to be delivered against it. 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
Similar Content3
Innovation 'Elevator Pitch':
DLS Access gives patients same-day access to their healthcare professionals via the web/smartphone/Skype or telephone achieving savings of £15 per patient with additional benefits.
Overview of Innovation:
DLS Access allows healthcare professionals to deal with increasing patient demand more efficiently and delivers a clear return on investment.  DLS Access is a cloud based service which is purchased on an annual per patient licence basis across the whole patient population.  The service is backed-up with executive level support and access to a DLS Client Delivery Manager to ensure successful deployment into your organisation.
 
Consultation requests are made by registered patients using their phone, a smartphone app or via a web form.  All requests are directed in to the ‘Health Hub’ and handled by trained call centre operatives.
 
The Health Hub team puts each patient on a call-back list for the requested healthcare professional who then aims to call the patient back within an hour, either by phone or Skype, whichever the patient requested.  This system provides same day primary care access for the group’s patient population, without opening for extended hours.  Out of hours demand is managed better and patients are seen quicker.
 
Results from the first deployment of DLS Access, which was through their partnership with Modality (previously Vitality) Partnership in the Prime Minister’s Wave 1 Challenge Fund programme have been more than hoped for.
 
DLS Access has demonstrated a £15 saving per patient across the group.
  • Over 65% of all health concerns are now dealt with remotely, within the hour.
  • Practices within the group have seen between 5-10% reduction in A&E attendance as a result of the DLS Access Service.
  • The Group have seen a 72% reduction in missed GP and ANP appointments. 
Many other benefits have been seen across Modality’s business as well as a return on investment from the savings the DLS Access project has achieved, these are outlined in the ‘Benefit to the NHS’ section below.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Person centred care
Benefit to NHS:
Results and benefits shown below have been tracked through Digital Life Sciences’ wave 1 Prime Minister’s Challenge Fund Programme, delivered in partnership with Modality (previously Vitality) Partnership between March 2013 and 2014.  The service continues to run, with the next steps of the digital strategy to be delivered through the Modality Vanguard programme.
 
The Modality Health Hub is one of the first truly digitally delivered primary care services and the first live example of how technology is enabling 65,000 patients to access their healthcare digitally.
 
DLS Access – Results for 65,000 patients
 
  • £15.49 saving per patient
  • 1600 patient hub contacts per day
  • 40 seconds average time calls are answered with in the Health Hub
  • 1,100 downloads of the Health Hub App to date
  • 400 website users per day
  • Over 4,000 registered online users
  • 68% of all health concerns are dealt with remotely within the hour
  • 32% of all patient demand now requires a face to face consultation
  • 72% reduction in missed GP and ANP appointments
  • Reduced consultation time – an average consultation is only 5 minutes, compared to the traditional 7 minute face to face consultation
  • Increased clinical capacity – early indications show up to a 10% increase in the number of patient consultations handled each day
  • Demand for appointments equalising – demand for appointments is equalising throughout the day and week, easing the historic 8am and Monday bottlenecks
  • Increasing online requests – an average of 50 online requests received per day with 28% received via the bespoke Android and iOS mobile apps 
“The new system is improving every day as patients and staff gets used to a different way of working.  Compared to the old system, I am able to speak to a greater number of patients per day and my patients only need to visit the surgery when absolutely necessary” – Dr Shaylor, Laurie Pike Health Centre
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The return on investment calculations for a DLS One Patient Access PMCF Wave 1 project, based on 65,000 patients (costs are based on a transformed operating and workforce model that incurs no additional cost, which can be achieved with clear leadership and a commitment to change across the project.
 
Annual savings for patient population:
DNA’s based on 72% reduction £209,950.00
A&E attendance based on 18% reduction £1,186,900.00
Total annual savings for patient population £1,396,850.00
 
Cost to install One Patient Access:
One Patient Access model of £5 per patient per annum £390,000.00
 
Return on Investment (shown as savings):
Return on investment for whole patient population £1,006,850.00
Per patient ROI £15.49
 
Many other benefits can be realised such as reduced consultation time, increased clinical capacity, demand for appointments equalising and an increase in online requests.
 
More information is available – click here.
 
“Just a quick note to congratulate you on the Modality Partnership app.  Personally, I think this is a great app which has allowed me to connect very easily and quickly to my doctor” – Modality Patient (comment from Modality Partnership website.
Current and planned activity: 
DLS Access is currently being rolled out to 'at scale' primary care providers including the South Worcestershire GP Federation and Aylesbury Vale GPs. The business is actively engaged in selling the service across the NHS.
What is the intellectual property status of your innovation?:
The I.P. is wholly owned by Digital Life Sciences Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Innovation 'Elevator Pitch':
AccessibleGP will nurture and encourage transformational behaviour change among patients and GP services facilitated by an interactive website and communications platform to promote patient self-care and reduce unnecessary GP appointments.
Overview of Innovation:
GPs are the most trusted source of health advice in the community.  But increasing workloads mean time available to support individual patients is reducing. Digital technologies introduced to ease some of the pressures, including the ability to book appointments and access medical records online, are rarely promoted in practices nor used by patients. New approaches to freeing up GP time and resources are urgently needed so they can devote more time to improving patient care.
AccessibleGP (AGP) is a model that facilitates transformational behaviour and service change. It aims to promote greater patient self-care, drive down unnecessary demand on GP time and enhance communication and information exchange between patients and GPs by using an interactive website and communications platform.
The platform sits behind local Practice websites, maintaining their individual look, feel and local content.  It offers improved content and functionality, with the ability to communicate:
  • personalised and reliable information and advice relevant to individual patient health care needs
  • relevant and timely information relating to particular patient ‘groups’.
It provides access to consultation notes, test results and recommended next steps, as well as motivational tools - such as the ability to set and monitor personal health goals with email reminders. It helps patients avoid accessing the wrong information online by linking directly to their GP and other trusted sources of advice, and has the potential for email, video and live chat functionality.
In the testing phase, ‘digital champions’ will be available to support the platform roll out within GP practices. They will help increase patient engagement and assist staff to embed its use into practice life. ‘Patient Activation Measurement’ (PAM) scores will be used to track any resulting health improvements and patient motivation increases. Reports generated from GP EMIS systems will also help monitor health improvements and GP usage.
Initial testing will focus on the top 10 health conditions frequently leading to unnecessary GP appointments. Concept testing has already been undertaken with a number of patient cohorts through a market research company. Patient engagement in co-designing the platform accessibility, ease of use and content will be central to the testing phase.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The AccessibleGP platform has the potential to offer a number of different benefits to the NHS focusing on reducing patient dependency on local GP practices and associated services and delivering prevention and early intervention by helping patients to have more control over their own health.
During the trial we will build a robust evidence base that tests the ability of the platform and engagement activities to:
  • enhance clinical capacity by reducing the number of unnecessary and unavoidable GP appointments while improving/maintaining overall GP accessibility
  • reduce re-occurrence of patient episodes associated with long-term conditions and therefore the draw on NHS primary and acute services
  • increase patient use of online services identifying any resulting in reductions in administrative demand on GP practices
  • support the current shift towards collaborative working between GP practices to improve access
  • help practices capitalise on additional NHS income generation opportunities.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
AccessibleGP has the potential to offer a number of benefits to the West Midlands population by:
  • improving interactions between patients and their GP, leading to greater patient satisfaction and confidence in the NHS/GP service
  • helping to maintain the ‘special relationship’ between patient and their GP
  • optimising the opportunity to promote key health messages to targeted audiences
  • improving patient motivation and engagement in managing their own health and adopting healthier lifestyles
  • creating greater clinical capacity for more vulnerable and urgent need patients
  • building greater long-term resilience among the West Midlands population leading to better health outcomes overall.
Current and planned activity: 
We have had initial interest in the product from a national NHS body, a number of GP consortiums and a local CCG. We have undertaken a concept scoping exercise with patients and practice staff by through support from a market research company. We are working with an experienced CRM and digital communication platform company, have engaged a number of Universities in the product development and are drawing together a number of GPs to act as 'critical friends' during the product testing and development.
We would value help with: intellectual property rights issues; funding to develop the IT platform and ensure its integration with EMIS and Vision; help to overcome Information Governance issues; and support to link with complementary innovations such as digital consent technology.
What is the intellectual property status of your innovation?:
Prime AccessibleGP as a name and logo is registered, however, copyright and patenting of intellectual property and the process for this is not yet completed and where guidance and support would be welcomed.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
To be completed
Measures:
To be completed
Adoption target:
To be completed
Read more
Hide details
Innovation 'Elevator Pitch':
MyDiabetesMyWay is a proven, scalable, cost-saving self-management platform/app empowering people with diabetes  to take ownership of their disease, data and treatment; delivering tailored support from NHS health record/  home recorded data.
Overview of Innovation:

MyDiabetesMyWay (MDMW) has been running since 2008 in NHS Scotland ,and is now being implemented in NHS England (e.g. Somerset, Manchester, NW London). MDMW is a cost saving (ROI>4:1) online web-based platform with over 50,000 registrants (covering all types of diabetes) funded by NHS/ government, giving patients access to their institutional (NHS) health records, integrating with home-recorded data, utilising algorithms and data linkage to drive highly tailored self-management advice and reports, communications tools and education resources.
MDMW has peer reviewed published evaluation and is an international exemplar having won many quality awards e.g. European ehealth adopters award (2017)/ Diabetes UK self-management award (2015)/ UK Quality in Diabetes Care award (2013). MDMW impacts on clinical outcomes e.g.HbA1C, is low cost (£1-2 per population patient per year license) and offers savings through reductions in complications/ efficiencies in care for NHS providers, and can be rapidly scaled across regions and countries.
 
THE PRODUCT:
MDMW is a portal/ app encompassing:
  • >200 digital educational resources (text, video, interactive content)
  • Patient electronic health record access (institutional NHS data)
  • Patient self-management decision support with data-driven tailored advice/web links
  • 6 QISMET accredited structured education courses (GDM, Type 1, Type 2)
  • Personalised care planning documents
  • Personalised care quality reporting (e.g. DUK 15 Care Measures)
  • Patient goal-setting tools
  • Communication tools; secure messaging with health care team/ peer discussion groups
  • Remote glucose monitoring support (community upload and sharing of home blood glucose (sugar) readings and feedback).
  • External social media channels
  • Responsive and accessible web/mobile platform design
"Patient access to diabetes records through My Diabetes My Way has meant a step change in the care and understanding of my condition to a level that it has never been. I am much more in control of my condition but importantly I now understand the goals that I should be achieving and am able to have a constructive discussion with my consultant. "

MyDiabetesMyWay is now being rolled out in sites across NHS England.

MyDiabetes Clinical is a complementary clinician facing platform delivering a EHR, automated clincian guidelien driven support, and individual and population analytics

http://www.mywaydigitalhealth.co.uk/
E: david.garrell@mwdh.co.uk
M: 07739 529737  
E: debbie.wake@mywaydigitalhealth.co.uk
M: 07904154101
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
MyDiabetesMyWay is a novel patient facing intervention which can directly impact on clinical outcomes, quality of life, and improve efficiencies in service delivery. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population. Good patient self-management driven by education, empowerment and motivation is key to good outcomes. Diabetes spending may rise over 10 years to c. 17% of the NHS budget. 

People with diabetes only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; i.e. - blood glucose monitoring, medication adjustment, appropriate daily foot care, weight management and dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications. 
 
MyDiabetesMyWay delivers cost savings and better outcomes for patients (ref: published evidence), it also improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs.
 
Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget.  Long-term conditions management needs to evolve to reap the potential benefits of data driven approaches. There is massive potential for wider lifestyle/home monitoring/institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.

MDMW can contribute to the local implementation of the NHS Long Term Plan. EG:

3.81 supporting delivery across primary care to enable more to acheive treatment targets
5.9 & 5.13 People seamlessly empowered by digital tools information and services/digital structured education.

Demonstrable through Tests 2/3/4 (£ releasing/reduce demand for care/reduce of unwarrant
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
MyDiabetesMyWay can directly impact clinical outcomes such as HbA1C, quality of life, motivation and knowledge, and improve efficiencies in service delivery (ROI at least 4:1)- see published evidence. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population over the age of 16. Good patient self-management driven by flexible access to good quaity information (available in a range of languages), structured education courses, empowerment and motivation is key to good outcomes. MDMW supports acheivement of local 3 treatment (BP, cholesterol and HbA1C) and structured education targets.
People with diabetes (PWD) only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; includes blood glucose (sugar) monitoring, medication adjustment, appropriate daily foot care, weight management and correct dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications. 
 
MyDiabetesMyWay delivers cost savings and  better outcomes for patients and  improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. This combination of empowered PWD and practitioners with a more complete picture can lead to more frequent co-production of health with the patient at the heart of decision making.

Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs. 
 
Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget.  Long-term conditions management needs to evolve to reap the benefits of data-driven approaches. There is massive potential for wider lifestyle/ home monitoring/ institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.
Current and planned activity: 
MDMW is currently deployed throughout NHS Scotland. MyWay Digital Health are now implemented/ing MDMW in sites in NHS England, including Somerset, NW London and Greater Manchester. We were selected as one of 11 NHS innovation accelerator programme fellows (2018 cohort) and the Digital Health London accelerator, both of which are supporting adoption.

We continue to develop the product including Artifical intelligence/machine learning, decision support and a corresponding clinician platform through Innovation funding.

This will further enable delivery of the long Term Plan and section 5.29:

"Decision support and AI ... technologies need to be embraced by the NHS, but also subjected to the same scrutiny that we would apply to any other medical technology. In the coming years AI will make it possible for many tasks to be automated, quality to increase and staff to focus on the complexity of human interactions that technology will never master.
See files for company skill profile.
What is the intellectual property status of your innovation?:
Intellectual Poperty for MDMW is fully assigned to the company from the University of Dundee for exploitation
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Co-Authors:
Regulatory Approvals:

IGToolkit was secured in late January 2018. We’ve adopted ISO 27001 policies and procedures (inc. provision for GDPR) and completed the Stage 1 assessment in early Feb 2018; the date for Stage 2 is May 2018 . The first big implementation of our system outside NHS Scotland is in Somerset, the Caldicott Guardian for Somerset CCG recently signed-off on our system, and it was endorsed by the Local Medical Committee as well as senior clinicians across the county. We aim to begin securing ISO 13485 as well as CE Device Marking later in 2018. We recently underwent a thorough successful regulatory review as part of the ITP assessment process (through ourmobilehealth)- report can be sent on for review.
Commercial information:
We already have a market ready My Diabetes My Way patient portal (operating at scale) although new features continue to be developed including remote monitoring and communication tools (July 2018) and a dedicated smartphone app (May 2018). We are also developing 2 new products MyDiabetes*Clinical (clinician diabetes EHR and quality improvement/ dashboard tools), and MyDiabetes*IQ (machine learning platform to support model building and decision support algorithms leading to alerting and notifications for patients and clinicians). 
for more information see; http://www.mywaydigitalhealth.co.uk/products/
Regional Scalability:
Implemented at scale across NHS Scotland since 2008 (currently> 35,000 registrants), Implementing in Somerset CCG and across NW London STP. Working on applications in Greater Manchester and other areas
Measures:
Previous Assesment in NHS Scotland:

MDMW clinical impact has been assessed (April 2017) using time-series analysis comparing HbA1c of active users with those in the inactive background patient population (control cohort) matched by age, duration of diabetes, socioeconomic status and gender (7147 interventions (registrants and active users) vs 36020 matched subjects). My Diabetes My Way (MDMW) users demonstrated a sustained 4 mmol/mol HbA1C reduction. Further health economic analysis based on UKPDS complications models and £1 per diabetes population annual charge/ 5-10% registration, suggests a return on investment of around 6:1. User surveys; 90% feel MDMW supports diabetes knowledge, self-management and motivation.

Ongoing Assessment:

- Identifying strategies/ barriers for successful implementation and uptake.
- Gather feedback on new product feature to assist in ongoing product development
- Assess changes in health outcomes, complications prevention and health economic benefits 
- Assess changes in working practices/ care delivery efficiencies e.g. impact on consultation numbers, face to face education, unnecessary screening tests


*Outcomes will be added to the health economic model
 

 
Adoption target:
We would aim to offer to everyone in the region with diabetes and rapidly onboard 5-10% of the entire diabetes population in your area in the first 12 months. Our intervention USP is low cost and scalability (at no additional per person cost).
Investment sought:
No investment sought currently
Read more
Hide details
3.3
2
Votes

5 3
Votings

Created by

Co-Authors:

Share and Follow